Apellis Pharmaceuticals Inc (NAS:APLS)
$ 39.68 -3.92 (-8.99%) Market Cap: 4.82 Bil Enterprise Value: 5.07 Bil PE Ratio: 0 PB Ratio: 18.04 GF Score: 38/100

Apellis Pharmaceuticals Inc, Aerie Pharmaceuticals, Aldeyra Therapeutics, and ProQR Therapeutic at Citi BioPharma Conference (Virtual) - Panel Transcript

Sep 10, 2020 / 01:50PM GMT
Release Date Price: $29.44 (-1.93%)
Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director

Okay. Great. I think we have everyone in the live session. So again, to the second panel that I'm moderating for the day, this is entitled Ophthalmology - Seeing 20/20 in 2020. I'm Yigal Nochomovitz. If you're interested in asking questions, you can either just e-mail me directly, [email protected], or there's a feature on the showcase virtual app where you can submit a question via chat. So just feel free to do that.

So it's my pleasure to have with me this morning 4 distinguished guests, all CEOs of their respective companies: from Aerie, Vince Anido; from Aldeyra, Todd Brady; from Apellis, Cedric Francois; and last but not least, from ProQR, Daniel de Boer. So welcome, all gentlemen. Thank you very much for taking the time to chat with us today.

Questions & Answers

Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director

I think what I'll do is just as a -- just very preliminarily, if each of you could give a very brief 1- to 2-minute overview of each

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot